Novo Nordisk (NVO-NYSE, $133.33) to Benefit From the First Change in US Guidance Regarding Childhood Obesity in 15 years.

gnosticcapital.com / Blog Archives

Novo Nordisk (NVO-NYSE, $133.33) to Benefit From the First Change in US Guidance Regarding Childhood Obesity in 15 years.

(all figures reported in USD unless otherwise stated) Novo Nordisk represents one of the top 7 investment positions in the Gnostic Model Portfolio Novo Nordisk, a Danish company, is the largest producer of diabetes and prescription weight loss medicines on…

Posted in Open Blog

published over 2 years ago


Previous

Grupo Aeroportaurio Del Sureste (ASR-NYSE, $256.74) Reports a 30.3 Million Passenger Throughput at Cancun International Airport for 2022.
published over 2 years ago

Next

Grupo Comercial Chedraui (CHDRAUIB-MX, $4.48 US) Provides 2023 Fiscal Guidance.
published over 2 years ago
See all items from the same source